BI Asset Management Fondsmaeglerselskab A S Sells 56,986 Shares of Moderna, Inc. (NASDAQ:MRNA)

BI Asset Management Fondsmaeglerselskab A S reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 87.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,551 shares of the company’s stock after selling 56,986 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Moderna were worth $911,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Proficio Capital Partners LLC increased its holdings in Moderna by 11.1% in the 1st quarter. Proficio Capital Partners LLC now owns 3,770 shares of the company’s stock valued at $402,000 after buying an additional 376 shares during the period. Nikko Asset Management Americas Inc. increased its holdings in Moderna by 156.9% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock valued at $79,044,000 after buying an additional 453,004 shares during the period. Daiwa Securities Group Inc. increased its holdings in Moderna by 10.3% in the 1st quarter. Daiwa Securities Group Inc. now owns 53,922 shares of the company’s stock valued at $5,746,000 after buying an additional 5,022 shares during the period. Nordea Investment Management AB increased its holdings in Moderna by 0.4% in the 1st quarter. Nordea Investment Management AB now owns 31,354 shares of the company’s stock valued at $3,372,000 after buying an additional 123 shares during the period. Finally, Fidelis Capital Partners LLC bought a new position in Moderna in the 1st quarter valued at about $121,000. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MRNA. UBS Group raised their price target on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Royal Bank of Canada raised their price target on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group raised their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Piper Sandler restated an “overweight” rating and issued a $214.00 price target on shares of Moderna in a research note on Thursday, June 27th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $134.02.

Moderna Stock Up 0.1 %

Shares of Moderna stock traded up $0.12 during trading on Wednesday, reaching $116.19. 754,612 shares of the company traded hands, compared to its average volume of 4,117,424. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a 50 day moving average price of $135.30 and a 200-day moving average price of $113.58. The firm has a market capitalization of $44.53 billion, a PE ratio of -7.41 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the prior year, the company posted $0.19 earnings per share. The business’s revenue was down 91.0% on a year-over-year basis. As a group, equities research analysts expect that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now owns 1,486,241 shares in the company, valued at $156,085,029.82. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CFO James M. Mock sold 648 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the completion of the sale, the chief financial officer now owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now owns 1,486,241 shares of the company’s stock, valued at approximately $156,085,029.82. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 381,239 shares of company stock worth $52,996,537. Insiders own 15.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.